Calidi Biotherapeutics, Inc. Common Stock
Key Metrics
Market Snapshot
About
Calidi Biotherapeutics, Inc. (CLDI) is a clinical-stage biotechnology company based in San Diego, California, focused on developing novel immunotherapies for treating cancer. The company is best known for its proprietary cell-based delivery platforms designed to enhance the effectiveness of oncolytic viruses, which are viruses engineered to selectively infect and destroy cancer cells.
The company's core technology involves using neural stem cells or other universal donor cells as protective carriers to deliver oncolytic viruses directly to tumor sites. This approach aims to shield the therapeutic viruses from being neutralized by the patient's immune system, allowing a higher dose to reach and attack hard-to-treat solid tumors. Calidi's lead product candidates leverage this delivery method. CLD-101 is in clinical trials for high-grade glioma, a severe brain cancer, while CLD-201 is being developed for other solid tumors such as breast and head and neck cancers. The company also has a pre-clinical candidate, CLD-401, targeting metastatic solid tumors.
Calidi operates through two primary technology platforms, NeuroNova and SuperNova, which form the foundation for its therapeutic pipeline. Its strategy is to advance these targeted therapies through clinical development to demonstrate their safety and efficacy in treating various cancers. Founded in 2014, the company's work represents an emerging approach within immuno-oncology, aiming to improve outcomes for patients with aggressive and recurrent cancers.